|Table of Contents|

The expression of CST4 and TGFB2 in esophageal cancer tissues and their clinical significance

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 14
Page:
2546-2554
Research Field:
Publishing date:

Info

Title:
The expression of CST4 and TGFB2 in esophageal cancer tissues and their clinical significance
Author(s):
GUO Jiayi1; HAN Yuanxing2; SONG Zhengyu1; ZHANG Haiping1; EDRISAWUT1; 3
1.Department of Thoracic Surgery,the First Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830054,China;2.Imaging Center,the First Affiliated Hospital of Xinjiang Medical University，Xinjiang Urumqi 830054,China;3.Xinjiang Medical University Jointly Established the State Key Laboratory of Causes and Prevention of High Incidence in Central Asia,Xinjiang Urumqi 830054,China.
Keywords:
esophagus cancer; CST4; TGFB2; prognosis
PACS:
R735.1
DOI:
10.3969/j.issn.1672-4992.2024.14.009
Abstract:
Objective:To investigate the expression of cysteine protease inhibitor S (CST4) and transforming growth factor β2 (TGFB2) in esophageal cancer tissues and their clinical significance.Methods:Bioinformatics analysis was used to understand the role of CST4 and TGFB2 in cancer.The expression levels of CST4 and TGFB2 were detected by immunohistochemistry in 68 patients with esophageal cancer diagnosed in our hospital from 2010 to 2019.Kaplan-Meier and COX regression models were used to analyze the effects of CST4 and TGFB2 on patient survival.Results:We found that CST4 and TGFB2 genes were mainly related to cell adhesion,migration and apoptosis through biological information analysis.We found that the positive expression rates of CST4 and TGFB2 in esophageal cancer tissues were significantly higher than those in normal esophageal tissues by immunohistochemistry.At the same time,CST4 and TGFB2 were significantly correlated with T stage and N stage of esophageal cancer patients.In addition,we followed up 68 patients for 5 years,and the median survival time was 26 months.We found that positive expression of CST4 (median survival time=21 months,P=0.004) and TGFB2 (median survival time=19 months,P=0.01) was significantly associated with lower 5-year overall survival (OS) in patients with esophageal cancer by Kaplan-Meier survival analysis.And when CST4 and TGFB2 co-expressed positive,the 5-year OS of patients was the lowest (median survival time=16 months,P=0.004).We found that both CST4 and TGFB2 were independent risk factors for poor prognosis of patients analyzed by COX regression model.At the same time,the expression levels of CST4 and TGFB2 were positively correlated.Conclusion:CST4 and TGFB2 are positively expressed in esophageal cancer tissues,and their positive expression may be related to the poor prognosis of patients.Therefore,CST4 and TGFB2 may be potential new markers for predicting the prognosis of patients with esophageal cancer.

References:

［1］ HAGENS ERC,VAN BERGE HENEGOUWEN MI,VAN SANDICK JW,et al.Distribution of lymph node metastases in esophageal carcinoma TIGER study:study protocol of a multinational observational study ［J］.BMC Cancer,2019,19(1):662.
［2］ HAGENS ERC,VAN BERGE HENEGOUWEN MI,GISBERTZ SS.Distribution of lymph node metastases in esophageal carcinoma patients undergoing upfront surgery:a systematic review ［J］.Cancers (Basel),2020,12(6):1592.
［3］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA Cancer J Clin,2021,71(3):209-249.
［4］ FREIJE JP,ABRAHAMSON M,OLAFSSON I,et al.Structure and expression of the gene encoding cystatin D,a novel human cysteine proteinase inhibitor ［J］.Journal of Biological Chemistry,1991,266(30):20538-20543.
［5］ TURK V,STOKA V,TURK D.Cystatins:biochemical and structural properties,and medical relevance ［J］.Frontiers in Bioscience,2008,13:5406-5420.
［6］ MARTINI D,GALLO A,VELLA S,et al.Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjogren's syndrome ［J］.Rheumatology (Oxford),2017,56(6):1031-1038.
［7］ SINGHANIA A,WALLINGTON JC,SMITH CG,et al.Multitissue transcriptomics delineates the diversity of airway T cell functions in asthma ［J］.Am J Respir Cell Mol Biol,2018,58(2):261-270.
［8］ KOOPAIE M,SALAMATI M,MONTAZERI R,et al.Salivary cystatin S levels in children with early childhood caries in comparison with caries-free children;statistical analysis and machine learning ［J］.BMC Oral Health,2021,21(1):650.
［9］ DOU Y,LV Y,ZHOU X,et al.Antibody-sandwich ELISA analysis of a novel blood biomarker of CST4 in gastrointestinal cancers ［J］.Onco Targets Ther,2018,11:1743-1756.
［10］ WANG S,WANG C,LIU O,et al.Prognostic value of immune-related cells and genes in the tumor microenvironment of ovarian cancer,especially CST4 ［J］.Life Sci,2021,277:119461.
［11］ CAI L,TU M,YIN X,et al.Combination of serum CST4 and DR-70 contributes to early diagnosis of colorectal cancer ［J］.Clin Chim Acta,2022,531:318-324.
［12］ BARTON DE,FOELLMER BE,DU J,et al.Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse:dispersion of TGF-beta gene family ［J］.Oncogene Res,1988,3(4):323-331.
［13］ BRAGADO P,ESTRADA Y,PARIKH F,et al.TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling ［J］.Nat Cell Biol,2013,15(11):1351-1361.
［14］ WELLER M,FONTANA A.The failure of current immunotherapy for malignant glioma.Tumor-derived TGF-beta,T-cell apoptosis,and the immune privilege of the brain ［J］.Brain Res Brain Res Rev,1995,21(2):128-151.
［15］ CORBET C,BASTIEN E,SANTIAGO DE JESUS JP,et al.TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells ［J］.Nat Commun,2020,11(1):454.
［16］ WU J,CHEN X,LIU X,et al.Autophagy regulates TGF-beta2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells ［J］.Mol Med Rep,2018,17(3):3607-3614.
［17］ ZHANG W,LI Y.miR-148a downregulates the expression of transforming growth factor-beta2 and SMAD2 in gastric cancer ［J］.Int J Oncol,2016,48(5):1877-1885.
［18］ MAHDAVINEZHAD A,YADEGARAZARI R,MOUSAVI-BAHAR SH,et al.Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue ［J］.Investig Clin Urol,2017,58(2):140-145.
［19］ SMITH AL,IWANAGA R,DRASIN DJ,et al.The miR-106b-25 cluster targets Smad7,activates TGF-beta signaling,and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer ［J］.Oncogene,2012,31(50):5162-5171.
［20］ JIANG XM,XU YL,YUAN LW,et al.TGFbeta2-mediated epithelial-mesenchymal transition and NF-kappaB pathway activation contribute to osimertinib resistance ［J］.Acta Pharmacol Sin,2021,42(3):451-459.
［21］ CERAMI E,GAO J,DOGRUSOZ U,et al.The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data ［J］.Cancer Discov,2012,2(5):401-404.
［22］ GAO J,AKSOY BA,DOGRUSOZ U,et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal ［J］.Sci Signal,2013,6(269):pl1.
［23］ KULESHOV MV,JONES MR,ROUILLARD AD,et al.Enrichr:a comprehensive gene set enrichment analysis web server 2016 update ［J］.Nucleic Acids Res,2016,44(W1):W90-97.
［24］ XIE Z,BAILEY A,KULESHOV MV,et al.Gene set knowledge discovery with Enrichr ［J］.Curr Protoc,2021,1(3):e90.
［25］ CHEN EY,TAN CM,KOU Y,et al.Enrichr:interactive and collaborative HTML5 gene list enrichment anal ysis tool ［J］.BMC Bioinformatics,2013,14:128.
［26］ HUANG DAW,SHERMAN BT,LEMPICKI RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources ［J］.Nat Protoc,2009,4(1):44-57.
［27］ SHERMAN BT,HAO M,QIU J,et al.DAVID:a web server for functional enrichment analysis and functional annotation of gene lists (2021 update) ［J］.Nucleic Acids Res,2022,50(W1):W216-W221.
［28］ LI C,TANG Z,ZHANG W,et al.GEPIA2021:integrating multiple deconvolution-based analysis into GEPIA ［J］.Nucleic Acids Res,2021,49(W1):W242-W246.
［29］ RICE TW,ISHWARAN H,FERGUSON MK,et al.Cancer of the esophagus and esophagogastric junction:an eighth edition staging primer ［J］.J Thorac Oncol,2017,12(1):36-42.
［30］ KELLY RJ.Emerging multimodality approaches to treat localized esophageal cancer ［J］.J Natl Compr Canc Netw,2019,17(8):1009-1014.
［31］ JOHNSTONE CN,PATTISON AD,GORRINGE KL,et al.Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer ［J］.Dis Model Mech,2018,11(5):dmm032250.
［32］ WATABE T,TAKAHASHI K,PIETRAS K,et al.Roles of TGF-beta signals in tumor microenvironment via regulation of the formation and plasticity of vascular system ［J］.Semin Cancer Biol,2023,92:130-138.
［33］ TRELFORD CB,DAGNINO L,DI GUGLIELMO GM.Transforming growth factor-beta in tumour development ［J］.Front Mol Biosci,2022,9:991612.
［34］ CIRILLO N,HASSONA Y,CELENTANO A,et al.Cancer-associated fibroblasts regulate keratinocyte cell-cell adhesion via TGF-β-dependent pathways in genotype-specific oral cancer ［J］.Carcinogenesis,2017,38(1):76-85.
［35］ LIU W,HUAI R,ZHANG Y,et al.Down-regulation expression of TGFB2-AS1 inhibits the proliferation,migration,invasion and induces apoptosis in HepG2 cells ［J］.Genes Genomics,2019,41(8):951-959.
［36］ TU Y,HAN J,DONG Q,et al.TGF-beta2 is a prognostic biomarker correlated with immune cell infiltration in colorectal cancer:A STROBE-compliant article ［J］.Medicine (Baltimore),2020,99(46):e23024.
［37］ YANG B,BAI J,SHI R,et al.TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer ［J］.Int Immunopharmacol,2020,84:106532.

Memo

Memo:
National Natural Science Foundation of China(No.81960498);国家自然科学基金（编号：81960498）；省部共建中亚高发病成因与防治国家重点实验室开放课题（编号：SKL-HIDCA-2021-21）
Last Update: 1900-01-01